Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia RADIAN's Five-Year ...

WAYNE, PA — Radian Group Inc. (NYSE: RDN) has announced it will host a conference call on Thursday, February 6, 2025, at 11:00 AM ET to discuss the company’s fourth quarter and full year 2024 ...

The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

General Atomics Systems Integration (GA-SI) and Radian Aerospace (“Radian”) have signed a Memorandum of Understanding (MOU) to advance next-generation aerospace technologies and explore broader ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise. Shortly after the turn of the century, Gilead Sciences took a ...